GlassScriptPhysician profile
Charles B Stanfield
NPI 1225091366
$8,125.23
in general payments reported to CMS, 2019-2025
44 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $772 · 2021: $145 · 2022: $1,277 · 2023: $1,899 · 2024: $1,677 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,181.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,029.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $815.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $721.53 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $675.63 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $632.34 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $572.37 | 2019-2024 | Evenity, Prolia, Otezla |
| Abbvie INC. | $536.27 | 2020-2025 | Vraylar, Ubrelvy, Synthroid |
| Astellas Pharma US INC | $440.55 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $417.07 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $410.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.20 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $152.72 | 2023-2025 | Ajovy |
| Dexcom, INC. | $124.36 | 2022-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $123.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $116.28 | 2019-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Stanfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.